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    BRIEF COMMUNICATION   
The evidence for any beneﬁ  t of screening is 
limited. The U.S. Preventive Services Task 
Force (  7  ) reviewed the available studies and 
concluded that it was unclear whether 
increased detection of prostate cancer from 
screening would reduce mortality and mor-
bidity, and a nested case  –  control study con-
cluded that it did not (  8  ). A European 
randomized trial reported a prostate cancer  –
  speciﬁ  c mortality reduction of about one in 
1400 after 9 years (  9  ), but a randomized trial 
in the United States found no reduction after 
7 or 10 years (  10  ). Thus, the best estimate 
seems to be a reduction of death from pros-
tate cancer of zero or one for every 1000 men 
screened, and the evidence is insufﬁ  cient to 
determine whether the beneﬁ  ts outweigh the 
harms, such as incontinence through over-
treatment of nonprogressive cancers (  7    –            10  ). 
  This study addresses two main ques-
tions: 1) Do women and men have realistic 
knowledge about the beneﬁ  ts of mammog-
raphy and PSA screening, respectively? and 
2) What information sources do they rely 
on? Here, we also addressed a related ques-
tion: Does the frequency of consulting a 
given source improve understanding of 
beneﬁ  ts? To our knowledge, this is the ﬁ  rst 
European survey of women’s and men’s per-
ceptions of the beneﬁ  ts of mammography 
and PSA screening, and the information 
sources that they rely on, with representa-
tive samples of the general population. 
  We conducted a survey of the public’s 
knowledge of the beneﬁ   ts of screening in 
                    Women and men in countries with modern 
health systems are confronted with the 
question of whether to participate in 
screening for breast cancer and prostate 
cancer. Yet, because screening can also lead 
to harms such as overtreatment, they need 
to understand the potential beneﬁ  ts  of 
these screening programs before they can 
make informed decisions about participat-
ing. Ideally, physicians, health pamphlets, 
and other information sources should assist 
in clarifying the actual size of beneﬁ  ts. 
  Screening for breast cancer with mam-
mography is widely encouraged by govern-
mental programs in both the European 
Union (EU) and the United States under 
the assumption that the screening pro-
grams save lives. In the case of breast can-
cer, an analysis of randomized trials with 
some 247    000 women aged 40  –  74 years 
showed that for every 1000 women who 
participated in screening, 3.9 diagnosed 
with breast cancer died, compared with 5.0 
among those who did not participate (  1  ). 
The follow-up time ranged between 5.8 
and 20.2 years. Thus, the absolute risk 
reduction was on the order of one in 1000 
(  2  ). The authors of a recent review of six 
trials involving half a million women esti-
mated the absolute risk reduction to be 
approximately one in 2000 (  3  ). Note that 
this beneﬁ  t relates to fewer breast cancer 
deaths; no reduction in mortality from all 
cancers or other causes was found. Whether 
the potential of screening to reduce breast 
cancer mortality outweighs the harms of 
overdiagnosis and overtreatment is still 
under discussion (  3    –            6  ). 
  Screening for prostate cancer with 
prostate-specific antigen (PSA) tests, 
although often encouraged by physicians and 
health information pamphlets, is not part of 
governmental screening programs and is 
recommended by few medical organizations. 
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eight countries of the EU and the European 
part of Russia. The eight EU countries 
include about 75% of people in the 27 EU 
countries and have a total population of 
about 500 million. The European part of 
Russia has a population of about 106 million 
out of a total of 143 million Russians. The 
percentage of women who have had mam-
mography is 57 in Germany, 78 in France, 76 
in Austria, 85 in the Netherlands, 66 in Italy, 
75 in the United Kingdom, 52 in Spain, 
47 in Poland (for women aged 45  –  54 years), 
and 19 in Russia (  11  ,  12  ). PSA screening pro-
grams do not exist in the nine countries, apart 
from a regional state-funded program in 
Tyrol, Austria. National health systems are 
predominantly ﬁ  nanced by taxes in the United 
Kingdom, Italy, and Poland and by contribu-
tions to social health insurance in Austria, 
France, Germany, and the Netherlands. 
  The data were collected as part of the 
European Consumer Study 2007 conducted 
between September and December 2006 by 
the Gesellschaft für Konsumforschung 
(GfK)      -Nürnberg Group (  13  ). Participants 
within each country were selected according 
to a quota method based on the ofﬁ  cial sta-
tistics concerning ﬁ  ve variables: region, size 
of household, sex, profession, and age (  14  ). 
The population in each country was ﬁ  rst 
segmented into subgroups based on these 
ﬁ  ve criteria, and within each subgroup, sub-
jects were sampled in proportion to their 
distribution in the entire country. Initial 
contacts were made by telephone; the inter-
views were conducted in the participants  ’   
homes. Consistent with earlier representa-
tive quota sampling surveys conducted by 
the GfK Group, across all countries, about 
60% of initial phone contacts resulted in a 
complete interview; in the remaining cases, 
sampling was continued until the quotas 
were met. Across all countries, the age dis-
tribution of participants was as follows: 
14  –  19 years (8.4%), 20  –  29 years (16.6%), 
30  –  39 years (18.0%), 40  –  49 years (18.4%), 
50  –  59 years (15.2%), 60  –  69 years (11.8%), 
and 70 years and older (11.5%). The total 
number of interviews was 10    228, with 2054 
in Germany and 2019 in Russia (the coun-
tries with the largest populations); 1005 in 
France, 1042 in the United Kingdom, 1007 
in Italy, 1019 in Poland, and 1024 in Spain; 
and 501 in Austria and 557 in the 
Netherlands (the two countries with the 
smallest populations). Participants were 
questioned in face-to-face personal inter-
      CONTEXT AND CAVEATS 
    Prior knowledge 
  Given the harms that can ensue from can-
cer screening procedures, people  ’  s deci-
sions as to whether to undergo cancer 
screening should be based on a realistic 
knowledge of its benefits.   
    Study design 
  Face-to-face-interviews were conducted 
among a representative sample of men and 
women in nine European countries, who 
were asked to choose among estimates of 
the number of fewer cancer-specific deaths 
(per 1000 individuals screened) by prostate-
specific antigen and mammography screen-
ing, respectively. Participants were also 
queried as to their sources of medical 
information.   
    Contribution 
  This study found dramatic (by an order of 
magnitude or more) overestimation of the 
benefits (absolute cancer-specific mortality 
reduction) of mammography and prostate-
specific antigen testing in the vast majority 
of women and men, respectively, in all 
countries surveyed. Frequent consultation 
of sources of medical information (includ-
ing physicians) was not associated with 
more realistic knowledge of the benefits of 
screening.   
    Implications 
  A basis for informed decisions by people 
about participation in screening for breast 
and prostate cancer is largely nonexistent 
in Europe, suggesting inadequacies in the 
information made available to the public.   
    Limitations 
  The influence of the public’s overestima-
tion of screening benefits on actual partici-
pation in screening was not addressed in 
this study, and the work was restricted to 
European countries.   
  From the Editors       
views with computer assistance, except in 
Russia, where for security reasons, inter-
viewers used paper and pencil. Using per-
sonal interviews avoided some of the 
problems of telephone interview methods, 
such as excluding poorer households with-
out telephones and hence introducing a 
bias in comparisons between countries. 
  As a measure of the perceived beneﬁ  t of 
mammography screening, we focused on 
cancer-speciﬁ  c mortality reduction because 
this is the endpoint typically communicated 
to the public (as opposed to total mortality 
reduction, for example). Women were ques-
tioned as follows: “1,000 women age 40 and 
older from the general population participate 
every 2 years in screening for breast cancer 
with mammography. After 10 years, the ben-
eﬁ  t is measured. Please estimate how many 
fewer women die from breast cancer in the 
group who participate in screening com-
pared to women who do not participate in 
screening.” The response alternatives were 
0, 1, 10, 50, 100, 200 (out of 1000), and “I 
don’t know.” For the perceived beneﬁ  t of 
PSA screening, men were questioned simi-
larly: “1,000 men age 50 and older from the 
general population participate every 2 years 
in screening for prostate cancer with PSA 
tests. After 10 years, the beneﬁ  t is measured. 
Please estimate how many fewer men die 
from prostate cancer in the group who par-
ticipate in screening compared to men who 
do not participate in screening.” The 
response alternatives were the same as those 
used for breast cancer screening. 
  To measure the frequency of informa-
tion sources used, we asked participants 
how often they used each of 14 sources that 
were divided into four categories as follows: 
family and/or friends (considered both a 
source and a category), experts (general 
practitioner and pharmacist), general media 
(television, popular magazines, daily news-
papers, and radio), and health-speciﬁ  c 
sources (pamphlets by health organizations, 
reference books, health insurance, Internet, 
consumer counseling, patient counseling, 
and self-help organizations). The response 
alternatives were never, rarely, sometimes, 
frequently, and don’t know. 
  We calculated the proportion of best 
estimates of screening beneﬁ  ts for all coun-
tries, all age groups, and for the group of 
citizens aged 50  –  60 years who are targeted 
by the screening campaigns. The propor-
tion of participants reporting use of sources 
of health information was calculated for all 
countries, all age groups, and all of the 14 
sources. Correlation coefﬁ  cients  between 
frequency of use of particular sources of 
health information and estimates of screen-
ing beneﬁ  ts were calculated. For mammog-
raphy screening, overestimation of beneﬁ  t 
was deﬁ  ned as the difference between the 
estimated beneﬁ   t (expressed in X out of 
1000 women) and one out of 1000. For 
instance, if the estimate was 50 in 1000, the 1218 Brief Communication | JNCI  Vol. 101, Issue 17  |  September 2, 2009
overestimation was 49 in 1000. A positive 
correlation means the higher the reported 
frequency of use, the larger the overestima-
tion. For PSA screening, the same proce-
dure was used except that estimates of 
0 were not scored as underestimation, but 
0 and 1 in 1000 were considered equally 
accurate. The correlations between overes-
timation and frequency of use of particular 
sources did not include participants who 
answered the question concerning the ben-
eﬁ  t of screening with “don’t know” (  Table 1   
shows the frequency of these responses).         
  Among all participants, only 1.5% of 
women (range across different countries: 
0.8%  –  2.9%) chose the best estimate for 
reduction in mortality due to breast cancer 
screening, that is, one woman for every 
1000 screened (  Table 1  ). Four times as 
many women answered that the beneﬁ  t was 
zero, and 92.1% overestimated the beneﬁ  t 
by at least one order of magnitude or 
answered that they did not know; this pro-
portion was higher (95.9%) in the eight 
EU countries due to the large proportion 
of no-beneﬁ   t estimates in Russia. The 
greatest overestimation was observed in 
France, the Netherlands, and the United 
Kingdom, where more than 40% of the 
women answered that the reduction in 
mortality was 100 or 200 women per 1000 
screened; in the United Kingdom, almost 
27% chose the highest ﬁ  gure. These three 
countries also had high participation rates 
in mammography screening. In Russia, 
where the availability of mammography 
equipment is limited (  15  ), the percentage 
of women who exhibited overestimation or 
did not know was the lowest of the coun-
tries surveyed, 82%. 
  Some of the women included in our 
study were younger than women targeted 
by screening programs and may have had 
little motivation to inform themselves 
about screening. However, in every coun-
try, the percentage of women who gave the 
best estimate was lower among those aged 
50  –  69 years and thus targeted by screening 
programs than among women younger 
than 50 years, and in every country but 
Russia, the proportion of 50- to 69-year-
old women giving the best estimate was 
smaller than in all other age groups. 
  In all countries surveyed, only 10.7% of 
men made reasonable estimates of the ben-
eﬁ  ts of prostate cancer screening (ie, deaths 
from prostate cancer prevented for every 
1000 men screened were less than or equal 
to one,   Table 2  ); 89.3% overestimated or 
answered that they did not know. Like their 
female counterparts, more than 40% of the 
French men estimated that screening would 
save 100 or 200 men from dying from pros-
tate cancer per 1000 screened. Men in 
Austria, the Netherlands, Spain, and the 
United Kingdom made similar overesti-
mates. As observed for women, the per-
centage of Russian men who overestimated 
the beneﬁ  ts or did not know was the lowest 
among the nine countries surveyed, 77%.         
  Similar to what was observed in women, 
the distribution of estimates made by men 
between the ages of 50 and 69 years was not 
more accurate than what was observed 
overall. The percentage of men who esti-
mated zero and one life saved decreased 
from 8.3% and 2.4%, respectively, in all 
age groups to 7.3% and 1.9%, respectively, 
among men aged 50  –  69 years. 
  Most (59%) women reported using one 
or more sources frequently, compared with 
47% of men (data not shown). In every coun-
try, older citizens searched for more infor-
mation than younger ones (data not shown). 
  Within the general categories of health 
information sources, family and friends, 
experts, general media, and health-speciﬁ  c 
sources, the correlations between the fre-
quencies of use of two sources were consis-
tently high (correlation coefﬁ  cients  >.5), 
whereas the correlations between sources 
from different categories were consistently 
lower (data not shown). The sources of 
health-related information reported most 
often were family and/or friends, followed 
in descending order by experts (general 
practitioner and pharmacist), general media 
(television was the most reported source in 
this category), and health-speciﬁ  c sources 
(among all participants, the seven sources 
in this category were the least used among 
the 14 sources). 
  Individual trends according to country 
were observed with respect to sources of 
health information (  Table 3  ). In Poland 
and Russia, family and/or friends were by 
far the most often reported source of infor-
mation. In Austria, France, Germany, Italy, 
and Spain, the general practitioner was the 
primary source of information, and, except 
for family and friends, little use was made 
of other sources in these countries. The 
Netherlands had the most even distribu-
tion of reported information sources. In 
the United Kingdom, the frequency of 
reported consultation of most sources of 
information was generally low. For only 
two sources did British citizens report 
higher than average frequencies.         
  Frequent consulting of sources was not 
associated with an increase in understand-
ing of the beneﬁ  ts of screening, but instead 
was often associated with overestimation. 
For the women in Austria, France, Germany, 
Poland, Russia, Spain, and the United 
Kingdom, there was no single source of 
information whose frequent use was associ-
ated with more accurate understanding of 
the beneﬁ  ts. By contrast, German women 
  Table 1    .       Estimated reduction of breast cancer mortality through regular participation in mammography screening (women only)  *     
    Reduction out of 1000
Percentage of responders     
  Mean Germany France Austria The Netherlands Italy United Kingdom Spain Poland Russia   
    None 6.4 1.4 0.8 2.4 0.7 5.3 2.0 3.9 4.2 16.1 
  1 1.5 0.8 1.3 2.9 1.4 1.3 1.9 2.7 0.8 1.7 
  10 11.7 12.8 15.7 11.0 10.7 10.6 10.3 6.9 9.7 12.4 
  50 18.9 21.3 21.7 22.1 22.6 17.4 13.9 11.7 20.5 20.1 
  100 15.0 16.8 21.5 20.8 22.5 13.9 17.0 11.3 14.8 10.8 
  200 15.2 13.7 23.7 11.0 20.1 15.2 26.9 15.7 17.1 6.8 
  Don’t know 31.4 33.1 15.3 29.8 22.1 36.3 28.0 48.0 32.9 32.1   
    *     Question: How many fewer women die from breast cancer in the group who participate in screening, compared to women who do not participate in screening? 
Mean across all nine countries is weighted by sample size.     jnci.oxfordjournals.org    JNCI | Brief Communication 1219
who more often consulted leaﬂ  ets and pam-
phlets from medical organizations (41% of 
Germans use this source;   Table 3  ) tended to 
overestimate the beneﬁ  t of mammography 
screening (  r   = .15, 95% conﬁ  dence interval 
[CI] = 0.07 to 0.23), as did French women 
(  r   = .12, 95% CI = 0.04 to 0.29). The 
German women who more often consulted 
a general practitioner (  r   = .10, 95% CI = 0.02 
to 0.18) or a pharmacist (  r   = .11, 95% CI = 
0.03 to 0.19) for health information also 
had less accurate understanding of beneﬁ  ts. 
  The only sources associated with 
improved knowledge of the beneﬁ  ts  of 
breast cancer screening were consumer 
counseling in the Netherlands (  r   =     .18, 
95% CI =     0.35 to     0.01) and in Italy 
(  r   =     0.17, 95% CI =     0.27 to     0.07) and 
patient counseling (  r   =     .16, 95% CI = 
    0.26 to     0.06) and self-help groups 
(  r   =     .12, 95% CI =     0.22 to     0.02) in 
Italy alone. 
  The results for PSA screening con-
ﬁ  rmed the general conclusion that consul-
tation of sources of medical information is 
not associated with knowledge of the ben-
eﬁ   ts of screening. For men in Austria, 
Germany, the Netherlands, Russia, and 
Spain, there was no single source whose 
frequent use was associated with better 
understanding of beneﬁ  ts.  Information 
from health insurances was associated with 
less overestimation in France (  r   =     .11, 
95% CI =     0.20 to     0.02), Poland (  r   = 
    .13, 95% CI =     0.25 to     0.01), and Italy 
(  r   =     .18, 95% CI =     0.29 to     0.08), and 
information from radio with less overesti-
mation in the United Kingdom (  r   =     .11, 
95% CI =     0.21 to     0.01). 
  For both mammography and PSA 
screening, there was no single country in 
which frequent consulting of general prac-
titioners and health pamphlets improved 
understanding of beneﬁ   ts. The overall 
effect across all nine countries was a slight 
positive correlation between overestima-
tion and frequency of consultation for 
general practitioners (  r   = .07, 95% CI = 
0.05 to 0.09) and health pamphlets (  r   = .06, 
95% CI = 0.04 to 0.08). 
  In this survey of more than 10    000 peo-
ple in nine European countries, 92% of 
women and 89% of men overestimated the 
beneﬁ  ts of mammography and PSA screen-
ing, respectively, by an order of magnitude 
or more, or stated that they did not know 
what the beneﬁ   ts were. This percentage 
was the lowest in Russia, with 82% for 
women and 77% for men. Consulting gen-
eral practitioners, health pamphlets, and 
other information sources generally did not 
increase accurate knowledge of beneﬁ  ts; the 
only major exception was information from 
health insurances about PSA screening. 
  Our use of a numerical response scale 
with particular categories (0, 1, 10, 50, 100, 
  Table 3    .       Percentage of participants reporting that they use specific sources of health information sometimes or frequently  *     
    Source Mean    †    Germany France Austria The Netherlands Italy United Kingdom Spain Poland Russia   
    Family/friends 62 65 60 61 50 62 53 47 67 69    ‡     
  General practitioner 59 68 69 68 50 79    ‡   53 72 43 44 
  Pharmacist 54 56 62 59 54 70    ‡   49 66 49 43 
  Television 43 45 57    ‡   43 51 38 35 32 42 42 
  Popular magazines 26 36 39    ‡   33 33 20 22 21 30 18 
  Daily newspaper 25 29 38    ‡   38 30 19 25 24 25 20 
  Radio 23 20 36    ‡   34 28 12 22 21 30 23 
  Leaflets and pamphlets 
  by health organizations
21 41    ‡   36 23 30 13 14 17 12 14 
  Reference books about 
 health  topics
20 20 23 23 27    ‡   15 25 15 15 22 
  Health insurance company 17 19 27 20 44 3 9 54    ‡   21 4 
  Internet (eg, health portals) 15 17 21 17 42    ‡   11 26 16 14 7 
  Consumer counseling 6 3 8 4 20    ‡   43 9 4 6  
  Patient counseling 6 2 3 3 20    ‡   65 8 9 5  
  Self-help organizations 4 3 5 2 8    ‡   24 6 3 4    
    *     Response alternatives were never, rarely, sometimes, frequently, and don’t know.   
      †       Mean across all nine countries was weighted by sample size.   
      ‡       Highest value for each source.     
  Table 2    .       Estimated reduction of prostate cancer mortality through regular participation in prostate-specific antigen screening (men only)  *     
    Reduction out of 1000
Percentage of responders     
  Mean Germany France Austria The Netherlands Italy United Kingdom Spain Poland Russia   
    None 8.3 3.8 1.6 4.1 3.0 5.7 0.5 9.3 5.0 20.3 
  1 2.4 2.3 2.7 3.5 2.2 1.8 0.9 4.3 0.7 2.9 
  10 14.4 17.7 16.9 24.4 11.5 11.9 15.9 17.0 13.9 10.7 
  50 19.3 23.0 21.6 27.1 20.2 18.5 17.3 25.1 17.9 15.0 
  100 14.0 17.2 21.1 20.8 20.3 9.2 15.6 18.8 14.5 7.3 
  200 11.8 9.7 20.2 14.2 14.2 12.2 19.5 17.9 11.3 3.4 
  Don’t know 29.8 26.3 15.9 5.9 28.5 40.6 30.2 7.6 36.7 40.4   
    *     Question: How many fewer men die from prostate cancer in the group who participate in screening, compared to men who do not participate in screening? 
Mean across all nine countries is weighted by sample size.     1220 Brief Communication | JNCI  Vol. 101, Issue 17  |  September 2, 2009
200) may have inﬂ  uenced participants  ’   esti-
mates and may have contributed to the large 
amount of overestimation observed. 
However, we have indirect evidence that an 
open response format might not reduce the 
degree of overestimation. At the time of this 
study (December 2006), we conducted an 
independent survey with a different polling 
institute (TNS Emnid) in Germany and with 
a new representative sample of 1018 citizens, 
in which we included the question: “Early 
detection with mammography reduces the 
risk of dying from breast cancer by 25%. 
Assume that 1,000 women aged 40 and older 
participate regularly in screening. How many 
fewer would die of breast cancer?” No 
response categories were used. The propor-
tion of correct answers was equally low, and 
overestimation was even larger, with a median 
estimate of 500 lives saved for every 1000 
women screened by mammography (  16  ). 
  This study did not assess perceived harms 
and economic costs, or whether the degree of 
overestimation of beneﬁ   t translates into 
higher participation in screening. An associa-
tion between overestimation and participa-
tion has been demonstrated in other studies, 
although this association was not observed 
for African American women (  17  ,  18  ). We 
also do not know whether the results are 
generalizable to other countries. Domenighetti 
et al      . (  19  ) found similar overestimation of 
mammography in telephone interviews con-
ducted with women in Switzerland and the 
United States and also reported overestima-
tion for women in the United Kingdom and 
Italy, but we are not aware of any surveys of 
the perceived beneﬁ  t of PSA tests that were 
conducted simultaneously in different coun-
tries. Nor are we aware of any representative 
nationwide survey of the perceived quantita-
tive beneﬁ  t of mammography or PSA screen-
ing in the United States. A study with 145 
American women with above-average educa-
tion reported an average perceived breast 
cancer  –  speciﬁ  c mortality reduction of 60 in 
1000 (  20  ), and a study of 207 women attend-
ing general internal medicine clinics in 
Wisconsin reported that 76% overestimated 
the relative risk reduction (  21  ). 
  We do not know why women and men 
overestimate the beneﬁ  ts of screening, but 
the results in   Table 3   may indicate potential 
reasons. After family and friends, whose 
information might actually derive from the 
other sources in  Table 3 , the most frequently 
mentioned sources were general practitioner 
and pharmacist. Studies on physicians  ’   lack 
of knowledge about the beneﬁ  ts of screening 
and conﬂ  icts of interest support the possibil-
ity that these professionals contribute to 
overestimation (  6  ,  16  ,  22  ). The observation 
that health-speciﬁ  c sources rarely improve 
understanding of screening (except for 
health insurance in several countries) also 
implicates these sources as a further poten-
tial cause, a hypothesis that is consistent with 
the ﬁ  ndings that few pamphlets, letters of 
invitation, and Web sites explain the size of 
the beneﬁ   t. If they do, the explanation is 
almost always in terms of a relative risk 
reduction rather than in the more transpar-
ent form of an absolute risk reduction (  16  ). 
  In conclusion, this study documents that 
information about the beneﬁ  ts of mammog-
raphy and PSA screening has not reached 
the general public in nine European coun-
tries, including the age group targeted by 
screening programs. Knowing the beneﬁ  t of 
a treatment is a necessary condition for 
informed consent and rational decision mak-
ing. At present, however, the available infor-
mation sources are not designed to 
communicate beneﬁ  ts clearly. As a conse-
quence, preconditions for informed deci-
sions about participation in screening are 
largely nonexistent in Europe.       
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